Document is current
Any future updates will be listed below
-
Authors
Smith, Anne
Tucker, Katherine L
Barnes, Rebecca K
Drakesmith, Cynthia Wright
Agwunobi, Adaku
Bateman, Paul A.
Forbes, Anna
de Lusignan, Simon
Ford, Gary A
Fujiwara, Takeshi
Hobbs, FD Richard
Koshiaris, Constantinos
Mant, Jonathan
McKinstry, Brian
Pollock, Stephanie
Rice, Cathy
Yang, Yaling
McManus, Richard J.
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR OTV ARC)
- License Information
-
More Information
Article History
Received: 6 September 2024
Accepted: 21 October 2024
First Online: 19 December 2024
Declarations
:
: The analyses of pseudonymised data were assessed by our sponsor as service evaluation not requiring individual consent and hence did not require ethical approval. Ethics approval for the qualitative analyses was provided by Wales REC 4 (21/WA/0280). Individual informed written consent will be gained for all participants in the qualitative work.
: Not applicable (this is a protocol with no individual data).
: The author(s) declare that they have no competing interests apart from: FDRH acknowledges part support as Director of the NIHR Applied Research Collaboration (ARC) Oxford Thames Valley, and Theme Lead of the NIHR OUH BRC. FDRH has also received occasional fees or expenses for speaking or consultancy from AZ, BI, Bayer, BMS/Pfizer, and Novartis not related to this research. RJMcM has previously received BP monitors for research purposes from Omron. The University of Oxford has licenced algorithms from the TASMINH4 trial to Omron for use in Hypertension-Plus. This work describes an independent evaluation of the impact of Hypertension-Plus in primary care and no authors receive personal payments associated with Hypertension-Plus.
